Recombinant Antibody Expression & Functional QC Validation | AtaGenix

From Sequence to Validated Antibody

Recombinant antibody expression offers advantages that traditional hybridoma supernatant cannot match: defined sequence, batch-to-batch consistency, scalable production, and the ability to engineer format (IgG, Fab, scFv) and species (chimeric, humanized) as needed. But these advantages only materialize if the expression and purification workflow delivers antibody that is pure, correctly folded, and functionally active.

AtaGenix's recombinant antibody expression pipeline covers the full workflow: codon-optimized gene synthesis, vector construction (heavy + light chain co-expression), mammalian transient or stable expression, Protein A/G affinity purification, and a multi-assay QC panel that verifies not just purity but biological function. The goal is to deliver antibody that works in the client's assay on the first attempt — not just a protein that looks correct on a gel.

QC Workflow

Every recombinant antibody produced by AtaGenix undergoes a standardized QC panel before release:

• SDS-PAGE (reducing & non-reducing): Confirms correct heavy/light chain molecular weight, assembly into full IgG, and overall purity. Non-reduced gel verifies intact interchain disulfide bonds.
• SEC-HPLC: Quantifies monomer content and detects aggregates or fragments that could affect assay performance.
• Endotoxin (LAL): Ensures the antibody meets thresholds for cell-based and in vivo applications.
• Concentration (A280): Accurate quantification for precise dosing in downstream experiments.
• Functional validation: Antigen-binding ELISA or SPR/BLI confirms that the expressed antibody retains specific target recognition. Additional application-specific testing (WB, IHC, IF, FC) available upon request.

Figure 1. Comprehensive QC panel for recombinant antibody expression. Data show strong target signals with low background across purity and functional readouts, confirming robust expression yield, high purity, correct assembly, and preserved antigen-binding activity — meeting release criteria for downstream research applications.

Results

The recombinant antibody met all release specifications: correct molecular weight on SDS-PAGE (both chains present under reducing conditions, intact IgG under non-reducing), high monomer content, and specific antigen recognition in functional assays with low background signal. The data confirm a stable, reproducible workflow capable of delivering assay-grade antibody material from sequence to validated reagent.

Standard Deliverables

This case study represents an anonymized project outcome. Results may vary depending on antibody sequence, expression system, and downstream application. All client information is subject to NDA.